A critique of semaglutide (Wegovy®) for obesity management NICE technology appraisal TA875
DOI:
https://doi.org/10.15277/bjd.2024.439Keywords:
obesity, Wegovy®, semaglutide, NICE TA875Abstract
Wegovy®, semaglutide 2.4 mg, is a glucagon-like peptide-1 analogue that has been approved by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with obesity in the National Health Service (NHS). In this review, we provide a reflection on NICE TA875 and its implementation in the NHS.
References
https://www.nice.org.uk/guidance/ta875; accessed on 5/10/2023
Wilding JPH, Batterham RL, Calanna S, et al.; the STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183
Davies M, Færch L, Jeppesen OK, et al.; the STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397(10278):971-84. https://doi.org/10.1016/S0140-6736(21)00213-0
Wadden TA, Bailey TS, Billings LK, et al.; the STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325(14):1403-13. https://doi.org/10.1001/jama.2021.1831
Rubino D, Abrahamsson N, Davies M, et al.; the STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325(14):1–12. https://doi.org/10.1001/jama.2021.3224
Garvey WT, Batterham RL, Bhatta M, et al.; the STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28(10):2083-91. https://doi.org/10.1038/s41591-022-02026-4
Kadowaki T, Isendahl J, Khalid U, et al.; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol 2022;10(3):193-206. https://doi.org/10.1016/S2213-8587(22)00008-0.
Rubino DM, Greenway FL, Khalid U, et al.; the STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. The STEP 8 Randomized Clinical Trial. JAMA 2022;327(2):138-150. https://doi.org/10.1001/jama.2021.23619.
https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2019/health-survey-for-england-2019-data-tables; accessed 05/10/2023.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; for the SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32. https://doi.org/10.1056/NEJMoa2307563.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.; the STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389(12):1069-84. https://doi.org/10.1056/NEJMoa2306963.
Wilding JPH, Batterham RL, Davies M, et al.; the STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–64. https://doi.org/10.1111/dom.14725.
https://www.nice.org.uk/guidance/TA924; accessed on 07/06/2024
Published
Issue
Section
License
Copyright (c) 2024 British Journal of Diabetes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
